Cancer stem cell-related factors are associated with the efficacy of pre-operative chemoradiotherapy for locally advanced rectal cancer

Hiroishi,Kazuaki; Inomata,Masafumi; Kashima,Kenji; Yasuda,Kazuhiro; Shiraishi,Norio; Yokoyama,Shigeo; Kitano,Seigo

doi:10.3892/etm.2011.243

Cancer stem cell-related factors are associated with the efficacy of pre-operative chemoradiotherapy for locally advanced rectal cancer

Authors:
- Kazuaki Hiroishi
- Masafumi Inomata
- Kenji Kashima
- Kazuhiro Yasuda
- Norio Shiraishi
- Shigeo Yokoyama
- Seigo Kitano
View Affiliations

Affiliations: Department of Surgery I, Oita University Faculty of Medicine, Yufu, Oita 879-5593, Japan, Department of Surgery I, Oita University Faculty of Medicine, Yufu, Oita 879-5593, Japan, Department of Diagnostic Pathology, Oita University Faculty of Medicine, Oita 879-5593, Japan
Published online on: March 21, 2011 https://doi.org/10.3892/etm.2011.243
Pages: 465-470

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pre-operative chemoradiotherapy (CRT) is an important neoadjuvant therapy for locally advanced rectal cancer. In the present study, we investigated the factors that influence the efficacy of pre-operative CRT in locally advanced rectal cancer. We divided 50 patients with locally advanced rectal carcinoma treated with pre-operative CRT into two groups according to the grade of tumor response to pre-operative CRT: low-sensitivity group and high-sensitivity group. As candidates for the prediction of sensitivity to pre-operative CRT, clinicopathological factors and 12 biomarkers, including factors related to tumor growth, cell cycle, apoptosis, tumor stroma and cancer stem cells, were examined immunohistochemically in 48 resected specimens. Thirty-one tumors showed high sensitivity and 19 showed low sensitivity to pre-operative CRT. The status of stem cell-related factors, CD133 and CD24, was significantly associated respectively with sensitivity to pre-operative CRT (P=0.003, P=0.029). In 10 tumors positive for both CD133 and CD24, low sensitivity to CRT was found in 9 (90%), whereas in 16 tumors negative for both CD133 and CD24, low sensitivity was found in 3 (19%). Other pathological parameters were not associated with tumor response to pre-operative CRT. In conclusion, overexpression of cancer stem cell-related factors, CD133 and CD24, is associated with the sensitivity of locally advanced rectal cancer to pre-operative CRT.

View Figures

View References

1.	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar
2.	Wolpin BM, Meyerhardt JA, Mamon HJ and Mayer RJ: Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 57:168–185. 2007. View Article : Google Scholar
3.	Sauer R, Becker H, Hohenberger W, et al: Pre-operative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
4.	Calvo FA, Serrano FJ, Diaz-González JA, et al: Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and pre-operative chemoradiation. Ann Oncol. 17:1103–1110. 2006. View Article : Google Scholar
5.	Ishii H, Iwatsuki M, Ieta K, et al: Cancer stem cells and chemoradiation resistance. Cancer Sci. 99:1871–1877. 2008. View Article : Google Scholar
6.	Haraguchi N, Inoue H, Tanaka F, et al: Cancer stem cells in human gastrointestinal cancers. Hum Cell. 19:24–29. 2006. View Article : Google Scholar
7.	Zlobec I, Vuong T and Compton CC: The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with pre-operative, high-dose-rate brachytherapy. Cancer. 106:284–286. 2005. View Article : Google Scholar
8.	Negri FV, Campanini N, Camisa R, et al: Biological predictive factors in rectal cancer treated with pre-operative radiotherapy or radiochemotherapy. Br J Cancer. 98:143–147. 2008. View Article : Google Scholar : PubMed/NCBI
9.	Zlobec I, Vuong T, Compton CC, et al: Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with pre-operative radiotherapy. Br J Cancer. 98:450–456. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Horst D, Kriegl L, Engel J, Kirchner T and Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 99:1285–1289. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Haraguchi N, Ohkuma M, Sakashita H, et al: CD133⁺CD24⁺ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol. 15:2927–2933. 2008.
12.	Choi D, Lee HW, Hur KY, et al: Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol. 15:2258–2264. 2009. View Article : Google Scholar : PubMed/NCBI
13.	He XX, Chen K, Yang J, et al: Macrophage migration inhibitory factor promotes colorectal cancer. Mol Med. 15:1–10. 2009.PubMed/NCBI
14.	Tanahashi J, Daa T, Gamachi A, et al: Human intestinal spirochetosis in Japan; its incidence, clinicopathologic features, and genotypic identification. Mod Pathol. 21:76–84. 2008.
15.	Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J and Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med. 1:511–529. 1983.PubMed/NCBI
16.	Cheuk W, Wong KO, Wong CS and Chan JK: Consistent immunostaining for cyclin D1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody. Am J Surg Pathol. 28:801–807. 2004. View Article : Google Scholar
17.	Paik SS, Jang KS, Song YS, et al: Reduced expression of Apaf-1 in colorectal carcinoma correlates with tumor progression and aggressive phenotype. Ann Surg Oncol. 14:3453–3459. 2007. View Article : Google Scholar : PubMed/NCBI
18.	Rosmorduc O, Wendum D, Corpechot C, et al: Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol. 155:1065–1073. 1999. View Article : Google Scholar
19.	Dubrovska A, Kim S, Salamone RJ, et al: The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA. 106:268–273. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Kim KH, Choi JS, Kim JM, et al: Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium. Histol Histopathol. 24:309–316. 2009.PubMed/NCBI
21.	Press MF, Hung G, Godolphin W and Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 54:2771–2777. 1994.
22.	Yada K, Shibata K, Matsumoto T, Ohta M, Yokoyama S and Kitano S: Protease-activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2 mRNA expression in human pancreatic cancer cells. J Surg Oncol. 89:79–85. 2005. View Article : Google Scholar : PubMed/NCBI
23.	Sadahiro S, Suzuki T, Maeda Y, et al: Predictors of tumor down-sizing and regression with pre-operative radiotherapy alone and with concomitant tegafur/uracil (UFT) for resectable advanced rectal adenocarcinoma. Hepatogastroenterology. 54:1107–1112. 2007.
24.	Japanese Society for Cancer of the Colon and Rectum: General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus: The 7th edition, revised version. Tokyo: Kanehara; 2009
25.	Lapidot T, Sirard C, Vormoor J, et al: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 367:645–648. 1994. View Article : Google Scholar : PubMed/NCBI
26.	Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
27.	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
28.	Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
29.	Ieta K, Tanaka F, Haraguchi N, et al: Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol. 15:638–648. 2008. View Article : Google Scholar : PubMed/NCBI
30.	Weichert W, Denkert C, Burkhardt M, et al: Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res. 11:6574–6581. 2005. View Article : Google Scholar : PubMed/NCBI
31.	Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
32.	Uchida N, Buck DW, He D, et al: Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA. 97:14720–14725. 2000. View Article : Google Scholar : PubMed/NCBI
33.	Bhatia M: AC133 expression in human stem cells. Leukemia. 15:1685–1688. 2001. View Article : Google Scholar : PubMed/NCBI
34.	Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI
35.	Fischer GF, Majdic O, Gadd S and Knapp W: Signal transduction in lymphocytic and myeloid cells via CD24, a new member of the phosphoinositol-anchored membrane molecules. J Immunol. 144:638–641. 1990.PubMed/NCBI
36.	Jackson D, Waibel R, Weber E, Bell J and Stahel RA: CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen in small-cell lung carcinomas. Cancer Res. 52:5264–5270. 1992.
37.	Akashi T, Shirasawa T and Hirokawa K: Gene expression of CD24 core polypeptide molecule in normal rat tissues and human tumor cell lines. Virchows Arch. 425:399–406. 1994. View Article : Google Scholar : PubMed/NCBI
38.	Roh MS, Colangelo LH, O'Connell MJ, et al: Pre-operative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 27:5124–5130. 2009. View Article : Google Scholar : PubMed/NCBI